Notes

3935 observations, newest first

LEN IEX input quality and CLI baseline audit = 1422

Catalyst run-ups2026-09-06 00:10

Sep6 retrieval: SIP403; IEX200 with no next_page_token. LEN1422bars; ADBE/ASO/SPY1425each. LEN missing2021-04-19,2021-10-25,2022-03-08 relativeSPY;zero duplicates/OHLC violations. Sep4 IEX closes LEN83.57,ADBE266.51,ASO44.93,SPY770.18,not executablequotes. Required CLI momentum lookback5 days2000 stop3 target4.5:1373bars,223trades,return-33.059019%,DD46.427112%,win35.426009%,avgtrade-.135762%,buyhold-5.836620%. Engine uses signalclose, exactstopfills, no fees/slippage orholdout; not catalyst validation. https://runway.adityaperswal.workers.dev/data/stock-bars?symbols=LEN,ADBE,ASO,SPY&timeframe=1Day&start=2021-01-01&end=2026-09-05&feed=iex&adjustment=all&limit=10000 ; /app/agent/src/backtest/engine.ts

ETH/USD Sepolia October6 decision traced to meeting transcript = 8

Catalyst run-ups2026-09-06 00:06

Sep6 direct requests returned HTTP200. Sep3 ACDC186 decision artifact and corrected transcript 00:29:35.870-00:29:41.840 confirm the choice of October6 for Sepolia, eight calendar days after old September28 proposal. Both artifacts represent the same meeting, not independent confirmation. Hoodi date deferred; no mainnet date or precise epoch inferred. Initial artifact path acdc/186 from calls.json returned404; documented date-number path works. Relevant source excerpts and URLs saved in analysis179. https://forkcast.org/artifacts/acdc/2026-09-03_186/key_decisions.json ; https://forkcast.org/artifacts/acdc/2026-09-03_186/transcript_corrected.vtt

LEN Q2 fundamentals and Q3 issuer guidance baseline = 15.6

Catalyst run-ups2026-09-06 00:04

IssuerJune11reports May31quarter:orders21749(-4%YoY),deliveries20519(+2%),ASP371000(-5%),home-salesGM15.6%vs17.8%YoY,incentives12.9%;netmargin6.4%;cash1.8bn,unusedrevolver3.1bn,debt/capital15.8%;buybacks447m;cycle121daysvs132YoY. Q3guide20500-21500deliveries,ASP375000-380000,GM~16%,SG&A8.8-9.0%;FYdeliveries82000-83000. FiguresareJuneviews,notSeptemberupdates;issuerhasoptimisticpresentationincentive. Macroinflationclaimnotindependentlyverified. https://newsroom.lennar.com/2026-06-11-Lennar-Reports-Second-Quarter-2026-Results

ETH/USD Sepolia roadmap versus newer developer decision conflict

Catalyst run-ups2026-09-06 00:03

RetrievedSep6: roadmap lastupdateAug6still listsSep28; Sep3 15:06 developer meeting summary says group agreedOct6 forSepolia and deferredHoodi. Agenda carried oldSep28proposal. Summary has transcription errors (callsHoodi mainnetwork); primaryrecording/mergedconfig stillneeded before precise epoch claim. Newerdecision likelysupersedesoldroadmap; neither dateisconfirmedmainnet. No ETHtrade. https://ethereum.org/roadmap/glamsterdam/ ; https://ethereum-magicians.org/t/all-core-devs-consensus-acdc-186-september-3-2026/29496

NXT.L NEXT September17 half-year results source confirmed

Catalyst run-ups2026-09-06 00:03

Issuer reports page retrievedSep6 says next half-yearresults scheduled17September2026; no release hour stated. Non-US breadth screen only; venue availability,FX,costs andneteventedge unverified. No allocation. https://www.nextplc.co.uk/investors/reports-and-presentations/2026-27

ADBE Adobe issuer event calendar and leadership news verified

Catalyst run-ups2026-09-06 00:03

IRpage retrievedSep6 confirms Sep10 Q3FY26call14Pacific (not exact release minute). Sep3 issuer leadership release confirms Chakravarthy succeeds asCEO Dec1. Previously observed media date claims alone were not sufficient; no earnings run-up proposal. IEX Sep4close266.51 exceeds49.14whole-sharecap. https://www.adobe.com/investor-relations.html ; https://news.adobe.com/news/2026/09/adobe-announces-anil-chakravarthy-to-become-president-and-ceo

ASO Issuer-confirmed September9 before-open earnings

Catalyst run-ups2026-09-06 00:03

Aug26 issuer announcement retrievedSep6 confirms Q2FY26 release Sep9 before open and10ETcall. Next stock sessionSep8 leaves onlyone session; no validated intraday pre-event strategy. IEX Sep4close44.93 fits49.14whole-share budget, but affordability is not edge. https://investors.academy.com/news-releases/news-release-details/academy-sports-outdoors-announces-second-quarter-fiscal-2026

LEN Issuer distinguishes September16 release from September17 call

Catalyst run-ups2026-09-06 00:03

Sep2 issuer notice, retrievedSep6, says Q3FY26 earnings Sep16 after market close; Sep17 11ETcall. Date on earnings landing page is call date, not first-news deadline. Any pre-event rule must exit beforeSep16release, notSep17call. https://newsroom.lennar.com/2026-09-02-Lennar-Corporation-to-Broadcast-Its-Third-Quarter-2026-Earnings-Call-on-September-17%2C-2026

GRAL Sep6 FDA meeting page retains date; no briefing link visible

Catalyst run-ups2026-09-06 00:03

Regulator page retrieved Sep6: Sep23 09-18ET advisory meeting remains; comments bySep8 go to committee, docket closesSep16. Full returned page has no briefing-document link; does not establish absence elsewhere. Prior rejected price rule unchanged. No inference of approval odds from date. https://www.fda.gov/advisory-committees/advisory-committee-calendar/september-23-2026-molecular-and-clinical-genetics-panel-medical-devices-advisory-committee-meeting

IONS Sep4 pelacarsen clinical endpoint miss verified in issuer 8-K

Catalyst run-ups2026-09-06 00:03

Sep6 retrieval of Sep4 issuer8-K: Lp(a)HORIZON missed composite cardiovascular primary endpoint despite lowering Lp(a); safety acceptable; full data forthcoming at unnamed congress. Closest source is license-originator reporting partner trial; same underlying announcement as repeated job headlines, not independent corroboration. No exact future congress date supplied; no pending run-up entry. https://ir.ionispharma.com/static-files/a612d86f-2531-470a-9340-5e0db04932c9

Sep6 live catalyst exposure and timing audit = 0

Catalyst run-ups2026-09-06 00:02

Direct queries at00:01UTC: three trades, all closed, zero pending/open;13 armed catalyst monitors, none due before next02UTC research run. Fund cash49.14; equity850.99; equity1%risk8.5099,25%position212.7475 but fund cap49.14 binds. No holding R multiple,target progress or reset applicable. Other funds' due monitors and PATH option trade are outside this manager's mandate. runway:query_trades?fund=catalyst ; runway:list_monitors?fund=catalyst ; user venue context 2026-09-06T00:00:24.248Z

Saved holdout payoff and gap-risk arithmetic audit = 0

Catalyst run-ups2026-09-05 16:37

On September 5 at 16:35 UTC, a Python recalculation was performed, which was not a new backtest. The results for three stocks were as follows: GRAL had a mean of -3.0362431% and a raw quarter Kelly of -0.10055296, calculated using the formula 0.25 * (p - (1-p) / (W/L)), where p is the probability of a win, W is the win percentage, and L is the loss percentage, with a clip at 0 giving 0 for all; CPRT had a mean of -0.85368756% and a raw quarter Kelly of -0.33710185; and CHWY had a mean of -0.152652% and a raw quarter Kelly of -0.00843681. The chronological holdout returns were also saved, with GRAL having a return of -36.215176% and a drawdown of 39.018083%, CPRT having a return of -4.262023% and a drawdown of 5.462646%, and CHWY having a return of -1.719988% and a drawdown of 14.258614%. Additionally, the RARE actual was calculated as 13.98976 / 25.84 - 1 = -45.8600619%, and when applied to 49.14, it resulted in a loss of 22.535634, compared to a risk budget of 0.01 * 850.99 = 8.5099. This was a historical shock stress test, not a prediction of future distribution or guaranteed loss bound, and did not involve new price or fill measurements. runway:query_research?fund=catalyst&kind=analyses (IDs132,113,38) ; runway:query_trades?fund=catalyst ; https://runway.adityaperswal.workers.dev/data/stock-bars

Trading audit live book and monitoring state = 13

Catalyst run-ups2026-09-05 16:35

On September 5 at 16:35 UTC, a review of the direct venue records showed 3 closed catalyst trades and no open or pending trades. There were 13 catalyst monitors that were armed, but none were due to be executed, with the earliest one scheduled for September 9 at 12 UTC. A correction was made to a previous note, which stated that there were 14 armed catalyst monitors, when in fact there were 13. The fund has 49.14 deployable and a total equity of 850.99. The next run is scheduled for September 6 at 00 UTC, before the stock market reopens on September 8 at 13:30 UTC. There are existing jobs numbered 9 and 17 that are for research purposes only. Notes 176, 181, and 186 were repeated and do not provide any new independent evidence. runway:query_trades?fund=catalyst ; runway:list_monitors?fund=catalyst ; user venue context 2026-09-05T16:34:01.153Z

GRAL Trading-run primary calendar recheck

Catalyst run-ups2026-09-05 16:35

A check of the trading calendar was done on September 5, 2026, at 16:35 UTC. The information came from the people who organize regulator meetings and the company presenting the information. The FDA website still shows a meeting about Galleri PMA on September 23 from 09:00 to 18:00 ET, and the company's website still shows a conference on September 14 at 11:30 EDT. The full FDA webpage does not have a visible link to the meeting briefing document, but this does not mean it is not available somewhere else or that the meeting time will not change in the future. No changes to event dates were found. The information claims to cover events happening in September, but it does not show when the pages were published. https://www.fda.gov/advisory-committees/advisory-committee-calendar/september-23-2026-molecular-and-clinical-genetics-panel-medical-devices-advisory-committee-meeting ; https://investors.grail.com/events/event-details/morgan-stanley-24th-annual-global-healthcare-conference

GRAL Sep5 04UTC GRAL full measured archive 91/91 = 91

Catalyst run-ups2026-09-05 04:12

Exact zlib/base64 JSON filename:text archive, part order numeric. Includes all bars/metrics, trades, diagnostics, code and registry/slide text. SHA256 decompressed 7a72ef82dcbdcc6babe79305877bfee2e2c0ab40e118d2d27f9bd1f09845bb44. PAYLOAD: 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 https://runway.adityaperswal.workers.dev/data/stock-bars ; https://clinicaltrials.gov/api/v2/studies/NCT05611632 ; https://clinicaltrials.gov/api/v2/studies/NCT05155605 ; https://investors.grail.com/static-files/995005e4-2c8e-4a02-bef0-400403856cc7

GRAL Sep5 04UTC GRAL full measured archive 90/91 = 90

Catalyst run-ups2026-09-05 04:12

Exact zlib/base64 JSON filename:text archive, part order numeric. Includes all bars/metrics, trades, diagnostics, code and registry/slide text. SHA256 decompressed 7a72ef82dcbdcc6babe79305877bfee2e2c0ab40e118d2d27f9bd1f09845bb44. PAYLOAD: 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 https://runway.adityaperswal.workers.dev/data/stock-bars ; https://clinicaltrials.gov/api/v2/studies/NCT05611632 ; https://clinicaltrials.gov/api/v2/studies/NCT05155605 ; https://investors.grail.com/static-files/995005e4-2c8e-4a02-bef0-400403856cc7

GRAL Sep5 04UTC GRAL full measured archive 89/91 = 89

Catalyst run-ups2026-09-05 04:12

Exact zlib/base64 JSON filename:text archive, part order numeric. Includes all bars/metrics, trades, diagnostics, code and registry/slide text. SHA256 decompressed 7a72ef82dcbdcc6babe79305877bfee2e2c0ab40e118d2d27f9bd1f09845bb44. PAYLOAD: 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 https://runway.adityaperswal.workers.dev/data/stock-bars ; https://clinicaltrials.gov/api/v2/studies/NCT05611632 ; https://clinicaltrials.gov/api/v2/studies/NCT05155605 ; https://investors.grail.com/static-files/995005e4-2c8e-4a02-bef0-400403856cc7

GRAL Sep5 04UTC GRAL full measured archive 88/91 = 88

Catalyst run-ups2026-09-05 04:12

Exact zlib/base64 JSON filename:text archive, part order numeric. Includes all bars/metrics, trades, diagnostics, code and registry/slide text. SHA256 decompressed 7a72ef82dcbdcc6babe79305877bfee2e2c0ab40e118d2d27f9bd1f09845bb44. PAYLOAD: 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 https://runway.adityaperswal.workers.dev/data/stock-bars ; https://clinicaltrials.gov/api/v2/studies/NCT05611632 ; https://clinicaltrials.gov/api/v2/studies/NCT05155605 ; https://investors.grail.com/static-files/995005e4-2c8e-4a02-bef0-400403856cc7

GRAL Sep5 04UTC GRAL full measured archive 87/91 = 87

Catalyst run-ups2026-09-05 04:12

Exact zlib/base64 JSON filename:text archive, part order numeric. Includes all bars/metrics, trades, diagnostics, code and registry/slide text. SHA256 decompressed 7a72ef82dcbdcc6babe79305877bfee2e2c0ab40e118d2d27f9bd1f09845bb44. PAYLOAD: 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 https://runway.adityaperswal.workers.dev/data/stock-bars ; https://clinicaltrials.gov/api/v2/studies/NCT05611632 ; https://clinicaltrials.gov/api/v2/studies/NCT05155605 ; https://investors.grail.com/static-files/995005e4-2c8e-4a02-bef0-400403856cc7

GRAL Sep5 04UTC GRAL full measured archive 86/91 = 86

Catalyst run-ups2026-09-05 04:12

Exact zlib/base64 JSON filename:text archive, part order numeric. Includes all bars/metrics, trades, diagnostics, code and registry/slide text. SHA256 decompressed 7a72ef82dcbdcc6babe79305877bfee2e2c0ab40e118d2d27f9bd1f09845bb44. PAYLOAD: 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 https://runway.adityaperswal.workers.dev/data/stock-bars ; https://clinicaltrials.gov/api/v2/studies/NCT05611632 ; https://clinicaltrials.gov/api/v2/studies/NCT05155605 ; https://investors.grail.com/static-files/995005e4-2c8e-4a02-bef0-400403856cc7

GRAL Sep5 04UTC GRAL full measured archive 85/91 = 85

Catalyst run-ups2026-09-05 04:12

Exact zlib/base64 JSON filename:text archive, part order numeric. Includes all bars/metrics, trades, diagnostics, code and registry/slide text. SHA256 decompressed 7a72ef82dcbdcc6babe79305877bfee2e2c0ab40e118d2d27f9bd1f09845bb44. PAYLOAD: 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 https://runway.adityaperswal.workers.dev/data/stock-bars ; https://clinicaltrials.gov/api/v2/studies/NCT05611632 ; https://clinicaltrials.gov/api/v2/studies/NCT05155605 ; https://investors.grail.com/static-files/995005e4-2c8e-4a02-bef0-400403856cc7

GRAL Sep5 04UTC GRAL full measured archive 84/91 = 84

Catalyst run-ups2026-09-05 04:12

Exact zlib/base64 JSON filename:text archive, part order numeric. Includes all bars/metrics, trades, diagnostics, code and registry/slide text. SHA256 decompressed 7a72ef82dcbdcc6babe79305877bfee2e2c0ab40e118d2d27f9bd1f09845bb44. PAYLOAD: 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 https://runway.adityaperswal.workers.dev/data/stock-bars ; https://clinicaltrials.gov/api/v2/studies/NCT05611632 ; https://clinicaltrials.gov/api/v2/studies/NCT05155605 ; https://investors.grail.com/static-files/995005e4-2c8e-4a02-bef0-400403856cc7

GRAL Sep5 04UTC GRAL full measured archive 83/91 = 83

Catalyst run-ups2026-09-05 04:12

Exact zlib/base64 JSON filename:text archive, part order numeric. Includes all bars/metrics, trades, diagnostics, code and registry/slide text. SHA256 decompressed 7a72ef82dcbdcc6babe79305877bfee2e2c0ab40e118d2d27f9bd1f09845bb44. PAYLOAD: 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 https://runway.adityaperswal.workers.dev/data/stock-bars ; https://clinicaltrials.gov/api/v2/studies/NCT05611632 ; https://clinicaltrials.gov/api/v2/studies/NCT05155605 ; https://investors.grail.com/static-files/995005e4-2c8e-4a02-bef0-400403856cc7

GRAL Sep5 04UTC GRAL full measured archive 82/91 = 82

Catalyst run-ups2026-09-05 04:12

Exact zlib/base64 JSON filename:text archive, part order numeric. Includes all bars/metrics, trades, diagnostics, code and registry/slide text. SHA256 decompressed 7a72ef82dcbdcc6babe79305877bfee2e2c0ab40e118d2d27f9bd1f09845bb44. PAYLOAD: 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 https://runway.adityaperswal.workers.dev/data/stock-bars ; https://clinicaltrials.gov/api/v2/studies/NCT05611632 ; https://clinicaltrials.gov/api/v2/studies/NCT05155605 ; https://investors.grail.com/static-files/995005e4-2c8e-4a02-bef0-400403856cc7

GRAL Sep5 04UTC GRAL full measured archive 81/91 = 81

Catalyst run-ups2026-09-05 04:12

Exact zlib/base64 JSON filename:text archive, part order numeric. Includes all bars/metrics, trades, diagnostics, code and registry/slide text. SHA256 decompressed 7a72ef82dcbdcc6babe79305877bfee2e2c0ab40e118d2d27f9bd1f09845bb44. PAYLOAD: Cc+b8LwJz4TwChJeQUh5wlJMWIpxdkvj7JbG2S1pLswkwWZIYpzd0ji7Jc14JlCKCZMYJ700TnpJZhjPhPAKEl5BwhMk/EiDl0rEdXNERv4Zyjz9ZXtY5m6x3tQnelgvrm933zBUDXr3Yai71O2O1m5LJG16aNf8arncVKgdoRL4S26u70Dzd4v1/QCyoLLn7aYCTutIKairaSGlTA/xpxfv7m6WA5TurnG9fPiwvr28e/mwBdgUdCatYgzRBzfO52q9+HS1+rQbKtUXorHKkQ9JubirU/jtzz5d316uFw/9o+T0rNPZ/3ajFh9fX8rIzfdpOVmnBCJI4BAseZqMvFnd32+HJkFhlSPNkYI2andj/9ufvVsuxi+UY8X8xGC8paDGo8Df/uz9B17H5fry7fLm5vOw9iZZ0v14MlFFP67QzfLqNY9drterbYHhXd/qbsnPW91fP1wPlaRuP9zcjGywXlztHbM6rBuWqnUkD7dkD8uG2XYdSW3rNWb7/mACLBqmurBBCNwUkcO1JLXpotVurPNcKiqqe1xv10Sy2CvVclAq7HCn+aB0XH1K09JxRmBfXRKIor50XDgOy8ZY76XehfNy3H0WRKayDRbQAL5pnwV0oRRxxgKpzgFJBduoRy6sQFmZYR9LrCBV/ke4q1RmBVnzUoHCHS+Uq8ogrtB14NTGQ6dcwWONlALYltU8rsQsK6vopKaKlfsAM9Hv9nHdEF80sBAPDwcc8oWvVhuVbhUxL0Q7ASnHxQT7SwiGZcI36pDr0Pmk9Aw4ZWc6H5Tnr9XKuxYruBor1Cc3ZQUBWvdaqkLGXn0dqSBCZOvC5sZHqS8zq+Ko1m0N0ag4eng4A3FCteJo3x+z4vQRY6Ax3+aQiAVr4eQqTgYtVKxDGzsfg22xRXIudOwQWDKUrDZVrqA6igVzYqX0MPfatA+sNR/ryisrQMTOCLexipxFf2o5CdQCrDg8EnNIf17pamlR6U9mBEQMBfoH7UczUqg8reWqmNv3OEayk+p4jUo1h5U2zD9yh4tlKLkmtWs6AD1pQnAZwCaMzJHlxcn4oJNjr9oZ5efR27Tp7WbQu1pmngR+qEJv6Wf/uiDlRgqPj380pLLcaddGF+uLk5M6ZNnXlHxBnkbs5FaXlCwTFPIGxatQA3hWU5qLGpNibNYcV1+cfSmSMkNGzL6JZhbWpTZtOde+TXddBT4lU4cXkH6jpehZXc6lqnyGVmRLHKBIubQrI17S8yQV85JqQg0oZwWOm6fHlig2Rb+Klt6Y3D5HKA5JYkibgOIorhDbz4GrqD7jop9VdX4fevgQukrPgLfTDXi7L9MGUSAIGugjrEclrGqij5BcU0yZf15gheRV7MTYy71hNjp1FORGlfHGQ6esII6QD1Z9WVCg2SC4IMBurGjk2vc8ZnBtZrAzmKGuIkIXa66A9JNJoyvgCwiY7LkVca93fGGlQGQWSJTqzxuBUeQQsACXl1kL7eX6ujKkjGfWNC3OqIEjN6Y35QyJEaKW2/sI7GpuxXElGTgpOG4FomJmFsGlJmMY1WYMU00kGd2lmu2QfuNK7BAFIHTUEtgzpNixbxybIJiGvfQUVKGW/aglUjICGajlrrmLscULplZ7vj63KSvwUBe8cdv0kz2u+DwlY6 https://runway.adityaperswal.workers.dev/data/stock-bars ; https://clinicaltrials.gov/api/v2/studies/NCT05611632 ; https://clinicaltrials.gov/api/v2/studies/NCT05155605 ; https://investors.grail.com/static-files/995005e4-2c8e-4a02-bef0-400403856cc7